Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey Study

20251 citationsJournal Articlegold Open Access

Authors

Kelli R. Franzenburg · Teva Pharmaceuticals (Czechia)

Rolf Hansen · Reckitt Benckiser (United States)

Mark Suett · Teva Pharmaceuticals (United Kingdom)

Ayelet Yaari · Teva Pharmaceuticals (Israel)

Anna S. Levin · Teva Pharmaceuticals (Israel)

Martin Sergerie · Global Affairs Canada

Sigal Kaplan

Abstract

Results from ADVANCE demonstrate that systemic and attitudinal factors influence LAI use by HCPs, and these factors vary by country. Enhancing HCP-patient communication may improve LAI acceptance.

Topics & Keywords

Schizophrenia research and treatment Family Caregiving in Mental Illness Mental Health and Patient Involvement

Publication Details

Published in: Schizophrenia Bulletin Open

Volume 7, Issue 1, pp. sgaf032-sgaf032

DOI: 10.1093/schizbullopen/sgaf032

Field-Weighted Citation Impact: 0.00

Command Palette

Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey Study

Authors

Abstract

Topics & Keywords

Publication Details